PMID- 24866329
OWN - NLM
STAT- MEDLINE
DCOM- 20141118
LR  - 20221207
IS  - 1744-7666 (Electronic)
IS  - 1465-6566 (Linking)
VI  - 15
IP  - 10
DP  - 2014 Jul
TI  - Effects of sitagliptin or mitiglinide as an add-on to acarbose on daily blood 
      glucose fluctuations measured by 72 h subcutaneous continuous glucose monitoring 
      in Japanese patients with type 2 diabetes: a prospective randomized study.
PG  - 1325-35
LID - 10.1517/14656566.2014.920323 [doi]
AB  - OBJECTIVE: Postprandial hyperglycemia and blood glucose fluctuations increase the 
      risk of macroangiopathy in patients with type 2 diabetes mellitus (T2DM). 
      However, few studies have examined the effects of oral hypoglycemic drugs on 
      blood glucose fluctuations in daily life. METHODS: Twenty-nine T2DM patients 
      treated with acarbose were randomized to receive either sitagliptin (14 patients) 
      or mitiglinide (15 patients) together with acarbose for 4 weeks. Patients were 
      then switched to a combination of 10 mg mitiglinide and 0.2 mg voglibose for 4 
      weeks. All patients wore a continuous glucose monitoring (CGM) device for 5 - 7 
      days in week 3 of each treatment period. RESULTS: The percentage of blood glucose 
      levels in the hyperglycemic range, blood glucose indices derived from 24-h CGM 
      profiles and the glycemic parameters (HbA1c, glycated albumin and fasting plasma 
      glucose) were significantly improved by adding sitagliptin or mitiglinide to 
      ongoing acarbose therapy. These parameters also tended to improve in the 
      mitiglinide/voglibose combination period. CONCLUSION: Daily blood glucose 
      fluctuations were significantly improved by adding sitagliptin or mitiglinide to 
      acarbose, and improved after switching to the mitiglinide/voglibose combination. 
      Larger controlled studies are needed to verify the effects of adding sitagliptin 
      or mitiglinide to acarbose on glucose fluctuations.
FAU - Osonoi, Takeshi
AU  - Osonoi T
AD  - NakaKinen Clinic , 745-5, Nakadai, Naka, Ibaraki , Japan t-osonoi@kensei-kai.com.
FAU - Saito, Miyoko
AU  - Saito M
FAU - Tamasawa, Atsuko
AU  - Tamasawa A
FAU - Ishida, Hidenori
AU  - Ishida H
FAU - Osonoi, Yusuke
AU  - Osonoi Y
LA  - eng
SI  - JPRN/UMIN000009525
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20140527
PL  - England
TA  - Expert Opin Pharmacother
JT  - Expert opinion on pharmacotherapy
JID - 100897346
RN  - 0 (Blood Glucose)
RN  - 0 (Glycation End Products, Advanced)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Isoindoles)
RN  - 0 (Pyrazines)
RN  - 0 (Serum Albumin)
RN  - 0 (Triazoles)
RN  - 4L6452S749 (Inositol)
RN  - D86I0XLB13 (mitiglinide)
RN  - S77P977AG8 (voglibose)
RN  - T58MSI464G (Acarbose)
RN  - TS63EW8X6F (Sitagliptin Phosphate)
RN  - 0 (Glycated Serum Albumin)
SB  - IM
EIN - Expert Opin Pharmacother. 2014 Aug;15(11):1637
MH  - Acarbose/*therapeutic use
MH  - Aged
MH  - Asian People
MH  - Blood Glucose/analysis
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Drug Substitution
MH  - Drug Therapy, Combination
MH  - Female
MH  - Glycation End Products, Advanced
MH  - Humans
MH  - Hyperglycemia/drug therapy
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Inositol/analogs & derivatives/therapeutic use
MH  - Isoindoles/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Prospective Studies
MH  - Pyrazines/*therapeutic use
MH  - Serum Albumin/analysis
MH  - Sitagliptin Phosphate
MH  - Triazoles/*therapeutic use
MH  - Glycated Serum Albumin
OTO - NOTNLM
OT  - acarbose
OT  - blood glucose fluctuations
OT  - continuous glucose monitoring
OT  - mitiglinide
OT  - mitiglinide/voglibose combination
OT  - sitagliptin
EDAT- 2014/05/29 06:00
MHDA- 2014/11/19 06:00
CRDT- 2014/05/29 06:00
PHST- 2014/05/29 06:00 [entrez]
PHST- 2014/05/29 06:00 [pubmed]
PHST- 2014/11/19 06:00 [medline]
AID - 10.1517/14656566.2014.920323 [doi]
PST - ppublish
SO  - Expert Opin Pharmacother. 2014 Jul;15(10):1325-35. doi: 
      10.1517/14656566.2014.920323. Epub 2014 May 27.